CAMBRIDGE, Mass -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination ...
Switch to Low Sulphur Fuel has Implications for Shore Based Industry Too says ICS. The International Chamber of Shipping (ICS), whose member national shipowners’ associations represent more than 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback